An analysis on the combination expression of HPV L1 capsid protein and p16INK4ain cervical lesions

Diagnostic Cytopathology

Volumn 38, Issue 8, 2010, Pages 573-578

  Huang, Min Zhu ^a   Li, Hong Bo ^b   Nie, Xin Min ^c   Wu, Xin Yin ^a   Jiang, Xiao Man ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b Guangzhou Kingmed Center for Clinical Laboratory   (China)

^c Central South University   (China)

Author keywords

Biomarkers; Human papillomavirus; Immunostaining; L1 protein; P16INK4a; Uterine cervical dysplasia

Indexed keywords

BIOLOGICAL MARKER; CYCLIN DEPENDENT KINASE INHIBITOR 2A; L1 CAPSID PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN; CAPSID PROTEIN; HPV L1 PROTEIN, HUMAN PAPILLOMAVIRUS; ONCOPROTEIN;

ABNORMAL LABORATORY RESULT; ADULT; AGED; ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE SEVERITY; FEMALE; HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOW GRADE SQUAMOUS INTRAEPITHELIAL LESION; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; STATISTICAL ANALYSIS; TISSUE INJURY; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; UTERINE CERVIX EPITHELIUM; WART VIRUS; ADOLESCENT; METABOLISM; MIDDLE AGED; PATHOLOGY; STAINING; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CAPSID PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; HUMANS; MIDDLE AGED; ONCOGENE PROTEINS, VIRAL; STAINING AND LABELING; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 77955162076     PISSN: 87551039     EISSN: 10970339     Source Type: Journal    
DOI: 10.1002/dc.21258     Document Type: Article

References (20)

1. Parkin DM, Bray F, Ferlay J, et al. Estimating the World Cancer Burden: Globocan 2000. Int J Cancer 2001;94:153-156.
2. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
3. McMurray HR, Nguyen D, Westbrook TF, et al. Biology of human papillomaviruses. Int J Exp Path 2001;82:15-33.
4. Sankarayanan R. Cervical cancer in developing countries. Trans R Soc Trop Med Hyg 2002;96:580-585.
5. INK4a immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia. Am J Surq Pathol 2002;26:1389-1399.
6. Ostor AG. Natural history of cervical intraepithelial neoplasia: A critical review. Int J Gynecol Pathol 1993;12:186-192.
7. Yoshida T, Sano T, Kanuma T, et al. Immunochemical analysis of HPV L1 capsid protein and p16 protein in liquid-based cytology samples from uterine cervical lesions. Cancer 2008;114:83-88.
8. Arafa M, Boniver J, Delvenne P. Detection of HPV-induced cervical (pre) neoplastic lesions: A tissue microarray (TMA) study. Appl Immunohistochem Mol Morphol 2008;16:422-432.
9. Cuschieri K, Wentzensen N. Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia. Cancer Epidemiol Biomarkers Prev 2008;17:2536-2545.
10. INK4a in its achievement Ginecol Obset Mex 2007;75:615-620.
11. Doorbar J. The papillomavirus life cycle. J Clin Virol 2005;32:S7-S15.
12. Hilfrich R, Hariri J. Prognostic relevance of human papillomavirus L1 capsid protein detection within mild and moderate dysplastic lesions of the cervix uteri in combination with p16 biomarker. Anal Quant Cytol Histol 2008;30:78-82.
13. Cantor SB, Atkinson EN, Cardenas-Turanzas M, et al. Natural history of cervical intraepithelial neoplasia: A meta-analysis. Acta Cytol 2005;49:405-415.
14. Melsheimer P, Kaul S, Dobeck S, et al. Immunocytochemical detection of human papillomavirus high risk type L1 capsid proteins in LSIL and HSIL as compared with detection of HPV L1 DNA. Acta Cytol 2003;47:124-128.
15. Stanley M. Immune response to human papillomavirus. Vaccine 2006;24:16-22.
16. Griesser H, Sander H, Hilfrich R, et al. Correlation of immunochemical detection of HPV L1 capsid protein in Pap smears with regression of High-risk HPV positive mild/moderate dysplasia. Anal Quant Cytol Histl 2004;26:241-245.
17. Hagensee ME, Koutsky LA, Lee SK, et al. Detection of cervical antibodies to human papillomavirus type 16 (HPV-16) capsid antigens in relation to detection of HPV-16 DNA and cervical lesions. J Infect Dis 2000;181:1234-1239.
18. Kim YT, Zhao M. Aberrant cell cycle regulation in cervical carcinoma. Yonsei Med J 2005;46:597-613.
19. INK4a and HPV L1 immunohistochemistry is helpful for estimating the behavior of low-grade dysplastic lesions of the cervix uter. Am J Surq Pathol 2008;32:1715-1720.
20. INK4a as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 2001;92:276-284.